Discovery strategies aimed to identify novel driver oncogenic lesions have succeeded in enrichment of the catalog of therapeutic targets, the most striking of which is BCR–ABL where TKI therapy has conferred tremendous benefits to CML patients with a sustained debulking of tumor burden. Here, BCR is linked to neoplasm.